ESPAC-4: Adjuvant Gemcitabine/Capecitabine in Resected Pancreatic Cancer

The ESPAC-4 trial found that adding capecitabine to gemcitabine in patients with resected pancreatic cancer resulted in an improved estimated 5-year survival rate.

Results of the phase III ESPAC-4 trial found that resected pancreatic cancer patients treated with the gemcitabine plus capecitabine had a better estimated 5-year survival rate compared with those treated with gemcitabine alone.

The data (abstract LBA4006) were presented by John P. Neoptolemos, MA, MB, BChir, MD, of the University of Liverpool in the United Kingdom, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3–7 in Chicago. In this video Dr. Neoptolemos discusses the results of the trial as well as the next steps in pancreatic cancer research.